Search Results for “advanced”

DiNAQOR partners with Siegfried to scale and commercialize DiNAMIQS as a best-in-class development and manufacturing platform for cell and gene therapies

May 4, 2023 by Andrew Hartmann

ZURICH-SCHLIEREN, Switzerland, May 4, 2023 – DiNAQOR, an innovative genetic medicine company headquartered in Switzerland with subsidiaries in Laguna Hills/California/USA and Hamburg/Germany focused on proprietary human-based tissue drug development and technology to enable organ-specific delivery of gene therapies and other therapeutics, today announced that it will sell a 95% stake in its subsidiary DiNAMIQS to … Read more

Thomas Eschenhagen, MD

February 2, 2023February 1, 2023 by admindqor

Thomas Eschenhagen, MD serves as DiNAQOR’s Chief Scientific Advisor and serves on the company’s Scientific Advisory Board. He is Professor of Pharmacology and Director of the Department of Experimental Pharmacology and Toxicology at the University Medical Center Hamburg Eppendorf, Germany and, since 2011, Speaker of the German Centre of Cardiovascular Research (DZHK). Dr. Eschenhagen pioneered … Read more

DiNAQOR Appoints Two Seasoned Executives to Leadership Team

January 9, 2023 by admindqor

Chris Rusconi to serve as Chief Development Officer; Steven Zelenkofske to take role of Chief Strategy Officer as DiNAQOR continues rapid growth

DiNAQOR Announces Research Collaboration with Children’s Medical Research Institute to Develop Novel, Cardiac Specific Capsids

January 10, 2022 by admindqor

DiNAQOR has entered into a research collaboration with Children’s Medical Research Institute (CMRI) in Australia to develop novel bioengineered adeno-associated virus (AAV) capsids to route gene therapy directly to human cardiac muscle.

Mauro Giacca, MD, PhD

February 2, 2023December 26, 2021 by admindqor

Mauro Giacca, MD, PhD, is Professor of Cardiovascular Sciences at the School of Cardiovascular Medicine & Sciences, King’s College London. Until 2019, he has served as the Director-General of the International Centre for Genetic Engineering and Biotechnology (ICGEB), an organization in the United Nations system based in Italy. From 2005, he is a Full Professor … Read more

Thomas Eschenhagen, MD

February 2, 2023December 22, 2021 by admindqor

Thomas Eschenhagen, MD, is Professor of Pharmacology and Director of the Department of Experimental Pharmacology and Toxicology at the University Medical Center Hamburg Eppendorf, Germany, and, since 2011, Speaker of the German Centre of Cardiovascular Research (DZHK). He is a member of the German Academy of Science Leopoldina (2008) and Past-President of the International Society … Read more

Mark Dehdashtian

December 22, 2021December 21, 2021 by admindqor

Mark Dehdashtian is a product development leader with decades of experience developing disruptive technologies and bringing new therapies to market to help patients address unmet medical needs. He serves as the Executive Vice President of DiNAQOR’s Medical Device division. Mr. Dehdashtian spent 25 years in leadership roles at Edwards Lifesciences, including serving as the company’s … Read more

DiNAQOR Appoints Medical Device Leader Mark Dehdashtian to Oversee New U.S.-Based Division, Device Development and Production

September 23, 2021 by admindqor

DiNAQOR has expanded its leadership team by appointing veteran medical device leader Mark Dehdashtian to serve as Executive Vice President, Medical Devices.

DiNAQOR Expands Board of Directors with Three Renowned Cardiovascular Industry and Academic Experts

September 22, 2021July 1, 2021 by admindqor

DiNAQOR has expanded the company’s board of directors with three new cardiovascular industry and academic experts: Louis G. Lange, M.D., Ph.D.; Steven Zelenkofske, D.O., M.S.; and Silke Rickert-Sperling, M.D.

BioMarin Extends Gene Therapy Leadership with DiNAQOR in a Preclinical Collaboration and License Agreement to Develop Gene Therapies for Rare Genetic Cardiomyopathies

May 4, 2020May 3, 2020 by admindqor

BioMarin Pharmaceutical has entered into a preclinical collaboration and license agreement with DiNAQOR to develop novel gene therapies to treat rare genetic cardiomyopathies.